Big News for Precision Oncology
The FDA has proposed the reclassification of numerous oncology companion diagnostics (CDx) from Class III to Class II, which would allow these tests to utilize the 510(k) pathway under the new device type specified at 21 CFR 866.6075. This is one of the most significant regulatory shifts for CDx in a decade and it arrives […]
Big News for Precision Oncology Read More »